We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US Patent Office's Patent Trial and Appeal Board (PTAB) on Thursday rebuffed Alvogen's filing requesting an inter partes review of a patent covering Celgene's Revlimid (lenalidomide).